A significant proportion of pharmaceuticals are fluorinated and selecting the site of fluorine incorporation can be an important beneficial part a drug development process. Here we describe initial experiments aimed at the development of a general method of selecting optimum sites on pro-drug molecules for fluorination, so that metabolic stability may be improved.
Introduction
A convenient, rapid in vitro chemical-microbial method for establishing the structures of oxidative metabolites of drug-like systems and subsequent improvement of substrate oxidative stability by site selective fluorination at pre-identified, oxidatively sensitive positions is reported here. This strategy may be of potential benefit to the drug development process.
Xenobiotics such as drugs and toxins are commonly metabolised in the liver prior to excretion, and the main class of enzyme involved is the cytochromes P450 (CYP). In humans there are 57 CYP isoforms responsible for oxidative or phase I metabolism of drugs, 1 and one of the key factors in drug design is modulating the rate of CYP-mediated transformation so that optimum efficacy can be achieved. In addition, as part of a drug development programme, the toxicity of metabolites must be assessed to complete regulatory approval. 2 Consequently, the identification, synthesis and isolation of drug metabolites are key stages in medicinal chemistry campaigns and, in general, in vivo studies are used to assess metabolite identity with obvious resource implications.
A simple in vitro method that successfully and accurately mimics mammalian metabolic processes would offer an attractive alternative to conventional resource-intensive bio-and medicinal chemistry approaches. Indeed, many chemical methods, such as the use of iron porphyrin systems, have been assessed as potential biomimetic cytochrome P450 mimics in vitro with varying degrees of success. 3 In complementary approaches, some microorganisms can transform drugs to mammalian metabolites, since they have CYP enzymes. In particular, the zygomycete fungus Cunninghamella elegans, which has been widely studied as a model of mammalian metabolism of xenobiotic compounds 4 , offers a non-chemical CYP biomimic.
Over 30% of currently available and commercially valuable pharmaceuticals owe their biological activity to the presence of fluorine atoms within their structures providing an indication of the importance of fluorine incorporation for modifying drug stability, lipophilicity and effective pH range. [5] [6] [7] [8] Indeed, a common strategy for increasing the half-life of a drug in vivo is to introduce a fluorine atom at the metabolically labile sites. 9 An example of how dramatic this approach can be is observed in the development of the cholesterol uptake inhibitor drug Ezetimibe (SCH 58325), where optimization of the lead compound (SCH4861) included fluorination of the phenyl ring, preventing oxidation to the corresponding phenol derivative, and substitution of a methoxy group with fluorine preventing demethylation (Fig 1) . These changes and other structural modifications reduced metabolic degradation to such levels whereby the required dose for activity could be decreased by 55 times, while increasing activity 400-fold. 10, 11 Therefore, in the sphere of fluorinated drug development, it would be very useful to easily determine the site of CYPcatalysed oxidation in a drug candidate in vitro, so that the incorporation of a fluorine atom is then made at the optimal position for increasing oxidative stability as a contributing approach to improving drug efficacy.
SCH48461
SCH58325 Ezetimib A common motif in several drug classes is the biphenyl system, 12 and various valuable pharmaceuticals bearing this structural unit are given in Fig. 2 . Previously, it has been demonstrated that biphenyl and fluorinated biphenyl 13, 14 derivatives are metabolised by C.
elegans in a similar fashion to mammals.
Telmarsartin Flurbiprofen

Valsarten
Figure 2. Examples of biphenyl-containing pharmaceuticals
In this paper, we describe proof-of-concept studies concerning a microbial-chemical method of identifying the most oxidatively sensitive sites in a range of model biphenyl substrates bearing a variety of functional groups by employing C. elegans and the bacterium Streptomyces griseus, which is known to also mimic human drug metabolism, 15, 16 to determine the sites of CYP-catalysed oxidation. The effect of strategic fluorination on metabolism was measured by further incubation of the appropriately fluorinated biphenyl system with the microorganisms in an overall strategy to develop systems that are oxidatively stable to CYP. This iterative process is shown in Scheme 1 where, ultimately, a fluorinated lead compound with appropriate metabolic stability can be identified in an early stage of the drug discovery process. 
Biphenyl-4-carboxylic acids
Biphenyl-4-carboxylic acid 1a was completely transformed by C. elegans, but remained untransformed by S. griseus. By GC-MS, one product was detected in the C. elegans extract, which had the expected mass spectrum of 4'-hydroxy-biphenyl-4-carboxylic acid 2a, and this was confirmed by 1 H NMR of the purified compound, which showed two diagnostic AX resonances centred at 7.53 and 6.86 ppm attributed to the two 1,4-disubstituted aromatic ring systems. Furthermore, this is the expected site of mammalian CYP-catalysed oxidation, based on previous observations. 17 Consequently, following the strategy outlined in Scheme 1, the corresponding 4'fluoro-biphenyl carboxylic acid 1b was synthesised by Suzuki-Miyaura coupling of 4fluorobenzene boronic acid with ethyl 4-bromobenzoate, followed by acid catalysed hydrolysis ( Table 1 , Supporting Information) following usual procedures and incubated with the microorganisms (Table 1) .
We observed that the 4'fluoro biphenyl carboxylic acid 1b is not transformed, demonstrating, in this case, that fluorine substitution in a position that favoured hydroxylation by CYP will block further oxidation thus exemplifying our strategy described in Scheme 1. (Table 3) . quantities of 2'-fluorobiphenyl methanol 3a shows that the hydroxylation of the aromatic ring is a slower process than oxidation of the CH 2 OH group whereas for the 3'-fluoro derivative, the methanol system is not observed indicating rapid hydroxylation, reflecting an increased electron donating effect of the CH 2 OH group on the 3'-fluoro system. Consequently, these in vitro studies provide more information regarding possible metabolite intermediates that may be generated compared to in vivo studies in which only the final metabolite is typically observed upon excretion.
The study was expanded by synthesising a range of fluorobiphenyl derivatives with varying functional groups by Suzuki-Miyaura coupling reactions ( Table 2 , Supporting Information) and incubating these with the microorganisms as described above (Table 1) .
4-Methyl biphenyl 1e
Incubation of 4-methyl biphenyl 1e with C. elegans resulted in almost complete transformation to 4'-hydroxybiphenyl-4-carboxylic acid 2a, indicating both oxidation of the methyl group and CYP-mediated hydroxylation. In S. griseus, two products were detected, 4-biphenyl methanol and biphenyl-4-carboxylic acid 1a, demonstrating that the oxidation of the substrate most likely occurs in a stepwise fashion; however, no hydroxylation of the rings occurs, which is consistent with our observations described above. When 4'-fluoro-4-methyl biphenyl 1f was incubated with the microorganisms, the transformation stopped at the corresponding carboxylic acid 1b with no ring oxidation, again consistent with results described above.
4-Methoxybiphenyl 1g
Incomplete demethylation of 4-methoxybiphenyl 1g to 2f was observed in C. elegans and S. griseus; however, in the bacterium, a highly unusual metabolite, 4-hydroxy-4-phenyl cyclohexane 2g, was also detected by GC-MS and the structure was identified by comparison with data in the NIST MS database. A sequence of intermediates for this unusual transformation is suggested in Scheme 4 and is consistent with a related pathway described by Gopishetty et al. 18 in which S. griseus transforms naphthalene to 4-hydroxy-1-tetralone, via 1-naphthol (Figure 4 ). 
S. griseus
4'-Fluorobiphenyl-4-carboxylic Acid 1b
A solution of 4'-fluorobiphenyl -4-carboxylic acid ethyl ester (0.71 g, 2.91 mmol) in THF (8 mL) and MeOH (8 mL) was treated with 2M NaOH (5mL) at room temperature overnight.
The organic solvent was evaporated leaving the aqueous layer which was acidified by the addition of 2M HCl. The solution was extracted using ethyl acetate and the organic layers 
Culture conditions
Streptomyces griseus ATCC 13273 was maintained on agar slants containing ISP4 medium.
The mycelia were inoculated into 250 mL Erlenmeyer flasks containing 30 mL sterile soya bean media consisting of soya bean meal (5 g/L), glycerol (20 g/L), yeast extract (5 g/L) and 
Metabolite analysis
Organic extracts were dried and the solid redissolved in ethyl acetate (1 ml Table S1 ).
